Condition: Neurological Diseases · Auto Immune Disease · Sponsor: Assistance Publique - Hôpitaux de Paris
The pathophysiology of neurological toxicities secondary to immune checkpoint inhibitors (ICIs) is unknown. Various mechanisms have been proposed: activation of cytotoxic CD8 T cells, autoantibodies via activation of B cells and CD4 cells, non-specific inflammation through the production of pro-inflammatory cytokines, and complement activation. The aim of this research is to characterise the pathophysiological mechanisms of neurotoxicities in cancer patients treated with ICIs.
This description comes directly from the study's public registry record.
Stefania Cuzzubbo, MD · 0171207467 · stefania.cuzzubbo@aphp.fr
Jérôme Lambert, MD PhD · 0142499742 · jerome.lambert@u-paris.fr
Always discuss trial participation with your own doctor first.
| Hôpital Bicêtre AP-HP | Le Kremlin-Bicêtre, France | Recruiting |
| Fondation Rotschild | Paris, France | Not Yet Recruiting |
| Hôpital Saint Louis AP-HP | Paris, France | Recruiting |
| Hôpital Saint Louis | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07456358